Ascendis Pharma ADR (ASND)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2025 | 06-2025 | 03-2025 | 12-2024 | 09-2024 | |
| Sales | 249,717 | 179,413 | 106,355 | 187,024 | 63,593 |
| Cost of Goods | 26,130 | 35,699 | 18,454 | 15,011 | 12,317 |
| Gross Profit | 223,587 | 143,714 | 87,901 | 172,014 | 51,277 |
| Operating Expenses | 210,862 | 204,523 | 198,142 | 170,434 | 157,972 |
| Operating Income | 12,854 | -60,110 | -109,787 | 1,590 | -106,379 |
| Interest Expense | 78,204 | 37,482 | 47,182 | -24,539 | 27,872 |
| Other Income | -1,712 | 57,852 | 58,399 | -64,971 | 26,294 |
| Pre-tax Income | -67,062 | -39,740 | -98,571 | -38,841 | -107,957 |
| Income Tax | 4,228 | 4,368 | 1,118 | 1,150 | 1,122 |
| Net Income Continuous | -71,290 | -44,108 | -99,689 | -39,991 | -109,078 |
| Net Income | $-71,290 | $-44,108 | $-99,689 | $-39,991 | $-109,078 |
| EPS Basic Total Ops | -1.17 | -0.73 | -1.67 | -0.62 | -1.89 |
| EPS Basic Continuous Ops | -1.17 | -0.73 | -1.66 | -0.62 | -1.90 |
| EPS Diluted Total Ops | -1.17 | -0.93 | -1.67 | -0.62 | -1.89 |
| EPS Diluted Continuous Ops | -1.17 | -0.69 | -1.66 | -0.62 | -1.90 |
| EPS Diluted Before Non-Recurring Items | N/A | -0.93 | -1.66 | -0.68 | -1.89 |
| EBITDA(a) | $17,851 | $-54,848 | $-104,999 | $6,201 | $-101,368 |